

MSOS Member Briefing

July 2023

MSOS Member Briefing July 2023

Moderated by: E. Robert Feroli, PharmD, FASHP



1

Practice Pearl

Cyclic Parenteral Nutrition – an EPIC solution

Jennifer Williams PharmD, BCPS
Mercy Medical Center – Cedar Rapids, Iowa

2

MSOS Member Briefing

July 2023

Mercy Medical Center Cedar Rapids, Iowa

- 'Stand-alone' health system
 - 450 bed community hospital
 - Urgent care, Specialty, and Primary care clinics
 - 2 ER locations
- EPIC system
 - Dedicated local team
- My position: Clinical pharmacist
 - Inpatient surgical/oncology unit
 - Oncology infusion clinic
 - Hybrid schedule (days/overnights)



3

Situation



Cyclic PN infusions do not run over 24 hours as continuous infusions



Require tapering on and off by nursing staff



Rate adjustments are getting delayed or missed

2 patients transferred to ICU for fluid overload related to rate change omissions in past 3 months

1 patient with overfeeding complications in past 6 months

4

MSOS Member Briefing

July 2023

Background

- Current state
 - Only indicators that an order is cyclic is title "Adult Cyclic PN" and administration instructions box (free text box) on MAR

Adult Cyclic TPN (Clinimix-E with Electrolytes) : 60 mL/hr : Intravenous : Continuous TPN :    

					1700 Due		
--	--	--	--	--	----------	--	--

Admin Instructions:
Start rate at 30 mL/hr for 1 hour starting at 1700.
Increase rate to 60 mL/hr for 18 hour(s) starting at 1800.
Decrease rate to 30 mL/hr for 1 hour starting at 1200, then stop.

Priority: Routine

Disposal: Return to Pharmacy Bin

5

Assessment

Delays or omissions in rate changes place patients at risk of overfeeding and other complications

Safety webinar at ASHP MidYear mentioned EPIC "taper button"

- Local EPIC team determined that it only autopopulates admin instructions
- Assumes volume dispensed = volume administered
 - Mercy utilizes premixed base solution product, dispensed in 1L increments

6

MSOS Member Briefing

July 2023

Recommendation

Project goal updated to using MAR prompts for rate changes

- Turn red when overdue, similar to other medications
- New PN entry for MAR created in Epic test environment, acts as "Due" time but for a rate change (no scanning, does not drop charge)

Process/Standard of work

- Nursing education
 - Range rate prompts review of admin instructions
 - Scan needed only for initial due time
- Pharmacist education
 - Labor-intensive order entry/verification, manual add of new due times

Approval via several committees

- Clinical Readiness committee: review for correct scanning/billing

7

Implementation

The screenshot displays the Epic MAR interface for an "Adult Cyclic TPN (Clinimix-E with Electrolytes)" order. The top section contains fields for "Action" (set to "Due"), "Date" (1800), "Time" (1800), and a "Comment" field. Below this, the "Reason" is "TPN Rate Change" and the "Due Action" is "Rate/Dose Change". The "Route" is "Intravenous" and the "Rate" is "40-90 mL/hr". The "Site" and "Infused Over" fields are also present.

The bottom section shows a timeline of due times: 1700, 1800, 1900, 1200, and 1300. The 1800 due time is highlighted with a blue box labeled "1800 Due (Rate/Dose Change)". The 1200 due time is highlighted with a yellow box labeled "1200 Due (Rate/Dose Change)". The 1259 due time is highlighted with a blue box labeled "1259 Due (Stopped)".

Below the timeline, there is a section for "Admin Instructions" and "Priority" (set to "Routine"). The instructions specify: "Start rate at 30 mL/hr for 1 hour starting at 1700. Increase rate to 50 mL/hr for 10 hours starting at 1800. Decrease rate to 30 mL/hr for 1 hour starting at 1200, then stop." The "Priority" is "Routine" and the "Disposition" is "Return to Pharmacy Bin".

8

MSOS Member Briefing

July 2023

Implementation

Frequency: Cyclic TPN - see admin | Continuous TPN

For: 20 | Hours | Days

Starting: Today 1700 | Ending: Tomorrow 1259

Scheduled Times: Hide Schedule

Rate: 40-90 mL/hr | 60 mL/hr | 75 mL/hr | 100 mL/hr | 125 mL/hr

Volume: 2,000 mL

Administer Over: 20 Hours | 24 Hours

Infusion Site: Central

Rate: 40-90 mL/hr

Last Rate: 40 mL/hr (0)

1656 NewBag 40 mL/hr

1754 Rate/Dose Change 90 mL/hr

9


Evaluation

- Reviewed every cyclic PN order for 6 months
 - Charging correctly, placeholders getting added correctly
 - 1 error in rate change
 - RN misread administration instructions
 - Patient had fluid overload, resolved with minor intervention
- Re-validated by Clinical Readiness committee
 - Triggered by pump integration project
 - Now able to assess real-time changes to rates
 - Less manual typing into MAR for RNs
 - Did update RN process to include dual sign-offs
 - Affirmed current process
 - do not use comment boxes with each rate due time, just admin instructions box on main order (matches process for insulin, heparin, crit care drips)

10


MSOS Member Briefing

July 2023




Next Project

- Perioperative PN > better communication
 - Fluids
 - Anesthesiology
 - Order discontinuation
 - Unintended
 - Intended (but then no taper)...



11



Questions?

Jennifer Williams PharmD, BCPS
Mercy Medical Center – Cedar Rapids, Iowa

12

MSOS Member Briefing

July 2023





What is the Prescription for Adherence?

Rachel DiPaolantonio, PharmD

13

FROM THE VIEW OF A COMMUNITY PHARMACIST




~130 pharmacy locations

Weis Markets is a regional grocery pharmacy chain with locations in Delaware, Maryland, New Jersey, New York, Pennsylvania, Virginia, and West Virginia.


14

MSOS Member Briefing

July 2023



PRESENTATION OBJECTIVES




Objective 1

✓ Understand the benefits of a medication alignment and automatic prescription refill service on both medication adherence and patient safety.

Objective 2

✓ Briefly discuss the study design and results of a mid-implementation research study conducted at a regional grocery chain pharmacy to investigate the feasibility of workflow strategies for enrollment in automatic prescription refill.

15




“Drugs don’t work in patients who don’t take them”

—
US Surgeon General C. Everett Coop


16

MSOS Member Briefing

July 2023



17




18

MSOS Member Briefing

July 2023

THE CHANGING VISION OF COMMUNITY PHARMACY



19

ISMP TIME GUARANTEE STUDY

Background

- Conducted by an ISMP Fellow with collaboration from the American Pharmacist Association (APhA)
- Inquired about the community pharmacist's viewpoint on the effect time guarantees have on pharmacy practice and prescription accuracy.



83%

Time guarantees were a contributing factor to medication errors made in community pharmacies.



44%

Were personally involved in a dispensing error related to hurrying to meet time guarantees.



37%

Of those involved in these dispensing errors, 37% did not report the error(s) that resulted.

Carson S. Prescription Drug Time Guarantees and Their Impact on Patient Safety in Community Pharmacies. ISMP Medication Safety Alert. 2012 Sep 6;1-4.c

20

MSOS Member Briefing

July 2023

THE HARM OF TIME GUARANTEES

May not allow for appropriate time to:

- Resolve insurance adjudication issues
- Clarify with prescribers
- Provide counseling to patients
- Perform a drug utilization review (DUR)
- Investigate drug interactions

How do we move away from this potentially harmful view of community pharmacy?

Carson S. Prescription Drug Time Guarantees and Their Impact on Patient Safety in Community Pharmacies. ISMP Medication Safety Alert. 2012 Sep 6;1-4.c

21

HOW DO YOU INCREASE ADHERENCE?

Medication Alignment

- Precursor to “medication synchronization” / “med sync”
- One time event
- Aligning the refill dates for a patient's chronic disease medications to a specific day, usually once a month.
- By hand or via 3rd party companies

Automatic Prescription Refill


- “Autofill”
- The pharmacy dispensing software incorporates the prescription into workflow at the scheduled refill time
- An automated process

Barnes B, Hincapié AL, Luder H, Kirby J, Frede S, Heaton PC. Appointment-based models: A comparison of three model designs in a large chain community pharmacy setting. J Am Pharm Assoc (2003). 2018 Mar-Apr;58(2):156-162.e1.

22

MSOS Member Briefing

July 2023



23




24

MSOS Member Briefing


July 2023

DATA COLLECTION - SURVEY



25

EXAMPLE SURVEY WORKFLOW



Quick summary: Ask the patient if they would like the medication in autofill when they request a refill.

26

MSOS Member Briefing

July 2023

RESULTS – MOST FEASIBLE WORKFLOW

Quick Summary

“Ask the patient if they would like the medication in autofill when they request a refill.”

Results

- 82% of participants responded “feasible (can implement as is)”

Other Findings

- Ranking: Most feasible
- Workload: requires the least number of steps, distributed among pharmacy team member type
- Was favored among the stores with the top autofill percentages

27

BOTTOM LINE

INCREASE ADHERENCE

Autofill helps patients avoid running out of medication

Use touch points with patients to educate about adherence programs

Go back to the basics and ask the patient at each opportunity you can

INCREASE SAFETY

Encourage change in patient perspective on the refill process and enrollment in autofill



Decreases “urgent” prescriptions & increases lead time for the pharmacy



Prevent development of at-risk behaviors by the pharmacy team caused by time guarantees

28

MSOS Member Briefing

July 2023

“The *unrushed* pharmacist will be the accurate pharmacist, and the *unhurried* patient will be the safe patient.”

Carson S. Prescription Drug Time Guarantees and Their Impact on Patient Safety in Community Pharmacies. ISMP Medication Safety Alert. 2012 Sep 6;1-4.c

29

Questions?

Rachel DiPaolantonio, PharmD
rachel.dipaolantonio@weismarkets.com

30

MSOS Member Briefing

July 2023

HAMST-R PRO:

explaining the reason why one-size CANNOT fit all

High-Alert Medication Stratification Tool – Revised, Prospective

Joel Daniel, PharmD, MS, CPPS

31

Who are we? Two health-systems?

Background

Basics of HAMST-R PRO

Usage

Utilization at our systems

CoxHealth

Facilities

- 6 hospitals
- 80+ clinics
- 1,194 licensed beds
- 25 counties served

Staff

- 12,178 employees
- 537 physicians
- 217 residency graduates
- 2,343 bedside nurses

CareChex
A Division of COMPANYS
AMERICA'S TOP QUALITY HOSPITALS

ACCREDITED
Hospital

QUALITY SYSTEM CERTIFIED
DNV
ISO 9001

MAGNET
RECOGNIZED
AMERICAN NURSES CREDENTIALING CENTER

CERTIFIED
Comprehensive Stroke Center

CERTIFIED
Top & Knee Replacement Center

32

MSOS Member Briefing

July 2023


Who are we? Two health-systems?

Background

Basics of
HAMST-R PRO

Usage

Utilization
at our
systems




Eskenazi Health

Facilities

- 333-bed safety-net, academic medical center
- Marion County, IN
- Level One Trauma Center, Burn Center, and Stroke Center
- 11 FQHCs

Staff

- 6,000 employees
- 1,200 physicians
- 1,000 bedside nurses
- 100 pharmacists, 90 pharmacy technicians



33

Standing on the shoulders of giants...

Background

Basics of
HAMST-R PRO

Usage

Utilization
at our
systems

ICPS A-Z List

What is in our toolbox?

A	P&T review and approval
B	Visual cues (ex. colored bins / stickers)
C	Warning or other alert labels used on product
D	Tall Man Lettering used
E	Checked in pharmacy only
F	Not stored in ADC
G	Special storage in ADC (ex. segregated / ADC cube)
H	Standardized order set
I	Independent double check by nurse prior to administration (documented)
J	Pharmacy prepares all doses
K	Medication dose adjustment / monitoring via machine
L	Medication dose adjustment / monitoring via pharmacy
M	Independent double check by pharmacy (ex. RIA dose cubic) (Note: independent double check by pharmacy is not required for all medications)
N	Use of smart infusion pumps
O	Check patient
P	Order intentionally (ex. to avoid look alike products, packaging)
Q	Document patient parameters, includes quantitative values (ex. WBC)
R	Clinical alerts or notifications via system
S	Only standard concentration(s) available
T	Pharmacy bag / manufacturer only
U	Use Code verification includes quarantine and confirmation (P's to U)
V	NO verbal or telephone orders
W	Assess and document patient's response, includes qualitative values
X	Limit access or staff that can administer
Y	Staff/Tellus algorithm only (meaning a resident couldn't order)
Z	Communication / special documentation

Heather Dossett, *et al.* Unpublished.

HAMST-R

What on our formulary is a high-alert medication?

ORIGINAL ARTICLE

High-Alert Medication Stratification Tool—Revised Phase II: A Multisite Study Examining the Validity, Interrater Reliability, and Ease of Use of the High-Alert Medication Stratification Tool—Revised

McKenzie R. Shenk, PharmD, Sandra C. Washburn, PharmD, BCSCP, Sarah S. Stephens, PharmD, BCPS, CPPS, Gregory P. Borge, PharmD, CPPS, ASHP, NREMT, James M. Curtis, PharmD, BCPS, Jacobson R. Horney, PharmD, James L. McCarthy, PharmD, BCPS, Kevin J. Duganovich, PharmD, BCPS, Andrew C. Freyette, PharmD, BCSCP, FCCM, Monica R. Mayall, PharmD, BCPS, BCOP, Heather A. Dossett, PharmD, MSc, BCPS, CPPS, and Todd A. Walroth, PharmD, BCPS, BCOP, FCCM

Todd Walroth, *et al.*

HAMST-R PRO

1. What new med should be considered a high-alert medication?
2. What items should we do to help prevent harm?


McKenzie Shenk, *et al.*

34

MSOS Member Briefing


July 2023

In essence, what is HAMST-R PRO?



35

How was it developed?



36

MSOS Member Briefing

July 2023

How to use the tool?

Category	Question	Clarification	Yes/No	Score
Background	Is this a look-alike, sound-alike drug?	Include medications, not limited to currently stocked products, which are recognized as LASA by any tertiary reference (e.g. LexiComp, Micromedex, ISMP (https://www.ismp.org/tools/confuseddrugnames.pdf), etc.) or internal approval body (e.g. Medication Safety Team).		0
Basics of HAMST-R PRO	Is there the opportunity/need to standardize concentration and/or strengths?	Do not consider tablet formulations. Do not answer yes if only one formulation is readily available. Examples include: morphine oral solution, intravenous heparin for continuous infusion, etc.		
Usage	Are there multiple formulations available?	Examples include: extended release products;		
Utilization at our systems	Development of standard protocols, policies, or order sets developed to guide prescribers needed for safety purposes?			
	Is there a need for the reversal agent to be on the order set?	Inclusion of reversal agent for order sets should be considered when potential adverse effects are rapid and severe. Example: naloxone.		
	Should there be maximum dose limits when prescribing?	Examples include: maximum weight-based dose (alteplase), maximum daily dose (IM olanzapine), maximum hard limit in infusion pump (diltiazem), etc.		
	Is adult weight-based dosing required when prescribing?			
	Should medication be hidden in CPOE outside of order sets?	Example: heparin infusions, insulin drips, neuromuscular blocker infusions, etc. Note: Consider other medications in the same class.		
	Is there clinical decision support (CDS) upon prescriber order entry?	CDS more active than standard order sentences.		
	Should the medication be considered restricted access to specialized prescribers?			

Example

- ISMP Reports
- Internal Reports
- External Reports
- Vulnerable Populations
- Risks in Prescribing
- Risks in Transcribing
- Risks in Storage
- Risk in Dispensing/Preparation
- Risks in Monitoring

37

How to use the tool?

Category	Question	Clarification	Yes/No	Score
Background	Is this a look-alike, sound-alike drug?	Include medications, not limited to currently stocked products, which are recognized as LASA by any tertiary reference (e.g. LexiComp, Micromedex, ISMP (https://www.ismp.org/tools/confuseddrugnames.pdf), etc.) or internal approval body (e.g. Medication Safety Team).	✓	0
Basics of HAMST-R PRO	Is there the opportunity/need to standardize concentration and/or strengths?	Do not consider tablet formulations. Do not answer yes if only one formulation is readily available. Examples include: morphine oral solution, intravenous heparin for continuous infusion, etc.	✗	
Usage	Are there multiple formulations available?	Examples include: extended-release products;	✓	
Utilization at our systems	Development of standard protocols, policies, or order sets developed to guide prescribers needed for safety purposes?		✗	
	Is there a need for the reversal agent to be on the order set?	Inclusion of reversal agent for order sets should be considered when potential adverse effects are rapid and severe. Example: naloxone.	✗	
	Should there be maximum dose limits when prescribing?	Examples include: maximum weight-based dose (alteplase), maximum daily dose (IM olanzapine), maximum hard limit in infusion pump (diltiazem), etc.	✗	
	Is adult weight-based dosing required when prescribing?		✗	
	Should medication be hidden in CPOE outside of order sets?	Example: heparin infusions, insulin drips, neuromuscular blocker infusions, etc. Note: Consider other medications in the same class.	✗	
	Is there clinical decision support (CDS) upon prescriber order entry?	CDS more active than standard order sentences.	✗	
	Should the medication be considered restricted access to specialized prescribers?		✓	


3/10 = 0 points

38

MSOS Member Briefing

July 2023


How to use the tool?



39

How to use the tool?

4 = HAM



40

MSOS Member Briefing

July 2023

How do we use it?

Background

Basics of HAMST-R PRO

Usage


Utilization at our systems

Isavuconazonium sulfate (Cresemba®)

4. Medication Safety Considerations

High-Alert Medication Stratification Tool-Revised Prospective Score (HAMST-R PRO)	0 (not a high alert medication)
ISMP Sound-Alike/Look-Alike Drug (SALAD)	No
ISMP reported safety concerns	None reported
REMS program	No program exists
Hazardous medication	No

Lee A, Han JM, Jun K, Heo KN, Grinalds MS, Washburn NC, Walroth TA, Ah YM, Lee JY. Development of the Korean High-Alert Medication Stratification Tool (K-HAMST). *Res in Clin Pharm* 2023;1:1-9. [accepted for publication]



41

How do we use it?


Background

Basics of HAMST-R PRO

Usage

Utilization at our systems

- Policy
 - Require a score of 4 or greater to be on high-alert medication list
- Require different levels of interventions
 - Score of 7 or higher **REQUIRES** a high-level intervention
- Incorporate into process
 - Initially part of the P&T process
 - Now informal portion of the post-P&T implementation process



COXHEALTH

SYSTEM POLICY – Patient Care (PC) / Medication Use

TITLE: Rx - High Risk Alert Medications
SUBMITTED BY: Joel Daniel, System Medication Safety Pharmacist
APPROVED BY: Hospitals Pharmacy & Therapeutics and Medical Executive Committees and Evidence Based Medicine Committee

PURPOSE:
 The organization will identify high-alert medications used in the system and the intervention strategies to manage risk.

POLICY:
 For each high-alert medication or group of medications identified, the organization will identify specific steps to improve safety appropriate steps within the Medication Management processes: selection and procurement, storage, ordering, validation, preparing, dispensing, administration and monitoring. These intervention strategies should mirror risk points within the Medication Management process.

The High-Alert Medication Stratification Tool – Revised (either retrospective version or prospective version, **HAMST-R** or **HAMST-R PRO** respectively) will be utilized in order to maintain medications on this list for the inpatient setting (Appendix A). Only scores of a 4 or higher on the tool will be considered for the High-Alert Medication list. Medications with a score of 7 or higher must be included on the list. Risk assessment may take on another form for the ambulatory/clinic setting.

SCOPE: All hospital and clinic locations

PROCEDURE:

42

MSOS Member Briefing


July 2023

How do we use it?

Background

Approach to Interventions:

1. Consider where in the medication management process the highest risks lie.
2. Make sure interventions address that process.



Basics of HAMST-R PRO

Recommendation	Intervention
A	Altered color/text in CPOE
B	Visual cues (ex: colored bins / stickers)
C	Warning or HIGH ALERT labels used on <u>product</u>
D	TALL Man Lettering used
E	Stored in pharmacy only
F	Frequency restriction (hard stop in Pharmacy)
G	Special storage in ADC (ex: special segregation or lidded bins)
H	Standardized order set
I	Independent double check by nurse prior to administration (documented)
J	Pharmacy prepares all doses
*KP	Medication dose adjustment / monitoring via pharmacy
*KT	Use of "Kit" (physical: IVPB + vial + adapter; or virtual)
*LDC	Independent double check by pharmacy (ex: BSA dose calcs) [Note: also encompasses Q and W]
M	Use of dosing charts, tools, protocols
N	Incorporate message within name

Usage

Recommendation	Intervention
O	Stock antidotes
P	Purchase intentionally (ex: to avoid look alike products, packaging)
Q	Document patient parameters, includes quantitative values (ex. INR, blood glucose, End Tidal CO2)
*RE	Clinical alerts or restrictions via system
*RS	Storage within robot and/or utilizing hub-and-spoke distribution system restriction
S	Only standard concentration(s) available
T	Premixed bags / manufacturer only
U	Bar Code Verification (includes quarantine and confirmation it's in system, process for adding a new NDC)
V	NO verbal or telephone orders
W	Assess and document patient's response, includes qualitative values (ex: pain, symptom management, sedation scores, bleeding)
X	Limit areas or staff that can administer
Y	Staff/Fellow signature only (meaning a resident couldn't order)
Z	Communication / special documentation

Adapted from the ICPS A-Z List

Utilization at our systems

Key	Intervention
	Low Level Intervention
	High Level Intervention

43

Questions?

Joel Daniel, PharmD, MS, CPPS

44

MSOS Member Briefing

July 2023



ISMP Update MSOS Briefing July 2023

Rita K. Jew, PharmD, MBA, BCPPS, FASHP
President
Institute for Safe Medication Practices

©2023 ISMP | www.ismp.org | 45

45

Articles on REMS Program




©2023 ISMP | www.ismp.org | 46

46

MSOS Member Briefing

July 2023

ISMP List of Confused Drug Names Updated



ISMP
Institute for Safe Medication Practices
An ECRI Affiliate

ISMP List of Confused Drug Names

This list of confused drug names, which includes look-alike and sound-alike name pairs, consists of those name pairs that have been published in the *ISMP Medication Safety Alert® Acute Care*, the *ISMP Medication Safety Alert® Community/Ambulatory Care*, and the *FDA and ISMP Lists of Look-Alike Drug Names with Recommended Tall Man Letters*. We hope you will use this list to determine which medications require special safeguards to reduce the risk of errors. This may include strategies such as: using both the brand and generic names on prescriptions and labels; including the purpose of the medication on prescriptions; configuring computer systems to require a minimum of the first five letters of a drug name during product searches to limit similar names from appearing together on the same screen; and changing the appearance of look-alike product names to draw attention to their differences. Both the US Food and Drug Administration (FDA) approved and the ISMP-recommended tall man (mixed case) letters have been included in this list.

Updated through February 2023

Drug Name	Confused Drug Name	Drug Name	Confused Drug Name
Abelcet	amphotericin B	ALfentanil*	SUFentanil*
Accupril	Aciphex	Akeran	Leukeran
acesaminophen	acetazolamide	Akeran	Myleran
acesaZOLAMIDE	acesaminophen	Allegra	Viagra



<https://www.ismp.org/recommendations/confused-drug-names-list>

©2023 ISMP | www.ismp.org | 47

47

Medication Safety Intensive



ISMP
Institute for Safe Medication Practices
An ECRI Affiliate

Consulting & Education Tools & Resources Publications & Memberships Error Reporting

Medication Safety Intensive Workshop

Maximize your error prevention efforts!

Workshop dates now available for 2023!

VIEW WORKSHOP DATES

This two-day virtual workshop is designed to help you successfully address current medication safety challenges that impact patient safety. Program faculty will provide you with the specific tools and resources needed to establish and sustain an aggressive, yet focused medication safety program.

Decades of data and learning from ISMP's Medication Error Reporting Programs make this a unique experience you will not find anywhere else. You will participate in hands-on practice in error analysis, evaluate root causes related to errors, learn how to effectively select high-leverage strategies, and use data to help sustain safety efforts within your organization.

This workshop is for practitioners at every level — including individuals who are new to medication safety roles and those looking to expand their understanding to support an effective medication safety system.

This workshop is conducted in English.



<https://www.ismp.org/education/msi-workshops>

©2023 ISMP | www.ismp.org | 48

48

- Virtual MSI
 - August 3-4, 2023
 - Oct 4-6, 2023
 - Nov 20-Dec 1, 2023
- Virtual MSI for Community & Specialty Pharmacy
 - Oct 20 & 27, 2023

MSOS Member Briefing

July 2023

We Want to Hear from You ...

ISMP/ECRI SURVEY ON DRUG, SUPPLY, AND EQUIPMENT SHORTAGES

ISMP and ECRI are conducting a short survey on the continuing crisis with **drug shortages and supply chain disruptions** resulting in ongoing patient safety and cost concerns. We are interested in learning about your experiences with drug, single-use supplies (e.g., tubing, syringes, cassettes), and durable medical equipment (e.g., infusion devices) shortages during the past 6 months. Please take a few minutes to complete the survey and submit your responses to ISMP and ECRI by **July 27, 2023**, by [clicking here](https://surveys.ismp.org/s3/Drug-Supply-and-Equipment-Shortage-Survey-2023). We plan to use the results of this survey to advocate for changes on a national level aimed at reducing the occurrence of serious shortages. Thank you for your participation in this survey.

— One more chance before the survey closes today, July 27, 2023



<https://surveys.ismp.org/s3/Drug-Supply-and-Equipment-Shortage-Survey-2023>

©2023 ISMP | www.ismp.org | 49

49

Last Call for ISMP Cheers Awards Nominations



Deadline: August 6, 2023

<https://www.ismp.org/cheers-awards/cheers-nominations>



©2023 ISMP | www.ismp.org | 50

50

MSOS Member Briefing

July 2023

Coming Soon...

- Applications for the Judy Smetzer Just Culture Champion Scholarships
 - A team of 3 individuals from a single organization
 - 15-hour Just Culture certification course
- Opens August 1st, 2023



<https://www.ismp.org/services/judy-smetzer-just-culture-champion-scholarships>

©2023 ISMP | www.ismp.org | 51

51

ISMP Represented at GEDSA Board

GEDSA Leadership Announcement

GEDSA announces the results of its Board of Directors election. John Bacon from MOOG has been re-elected as Treasurer. Joseph Paone from Cardinal Health has been re-elected as Secretary. Cynthia Reddick, Stacie Ethington, and Shannon Bertagnoli have been elected to represent the Board's three clinical seats. Congratulations to all the Board Members! We look forward to your leadership and participation in GEDSA's mission of advancing patient safety.

GEDSA welcomes its new Board of Directors members:

- Shannon Bertagnoli, Pharm.D., Medication Safety Specialist, Publications, Institute for Safe Medication Practices (ISMP)
- Stacie J. Ethington, MSN, RN, Medication Safety Nurse Specialist, Nebraska Medicine
- Cynthia Reddick, RD, CNSC, Home Tube Feeding Expert, Educator, and Strategist, HEN Consultant

John Bacon Joseph Paone Shannon Bertagnoli

Cynthia Reddick Stacie Ethington



©2023 ISMP | www.ismp.org | 52

52

MSOS Member Briefing

July 2023

Questions?



- A copy of today's slides will be posted on our website
- Next MSOS Briefing date – September 28, 2023.

